1 Department of Colorectal Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 2 Department ...

1 Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, China 2 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

In the majority of patients with chronic gastrointestinal and liver diseases, maintenance therapy is required during pregnancy to control the disease, and disease follow-up or disease control might ...

Background There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s oesophagus (BE). Objective To develop and ...

Correspondence to Brian B Scott, Department of Medicine, Lincoln County Hospital, Lincoln LN2 5QY, UK; drbbscott{at}aol.com Iron deficiency anaemia (IDA) occurs in 2–5% of adult men and postmenopausal ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Background Injured or reactive biliary epithelial cells participate in most chronic liver injuries in a process referred to as ductular reaction, which involves multicellular interactions with marked ...

12 Centre for Digestive Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden 13 Centre for Digestive Diseases, Karolinska University Hospital Solna, Stockholm, Sweden Objective This ...

Background Recommendations for the first postpolypectomy surveillance colonoscopy (SC1), based on stratifying postpolypectomy colorectal cancer (CRC) risk, are well established. Limited data inform ...

6 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 7 Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada ...

Background PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in ...